Study on immunohistochemical staining of laminin correlation with liver metastasis

在免疫组化研究中，我们发现35%的大肠癌基底膜层粘连蛋白（laminin）染色阳性。并且我们发现产生基底膜的癌（BMPC）的肝转移率高于无基底膜的结直肠癌（non-BMPC）。肝转移复发率前者为67%，后者仅为8%。我们应用层粘连蛋白（laminin，LN）的BM分析检测了结直肠癌肝转移的危险性，发现BMPC与结直肠癌肝转移的相关性（敏感性：75.6%，特异性：85.7%，准确性：83.9%，阴性：94.2%），据此可预测结直肠癌肝转移的危险性。一种是存在于每个癌巢周围的BM（A型），另一种是存在于几个癌巢周围的BM（B型）。A型与B型的肝转移率分别为85.7%和41.2%，差异有统计学意义。相比之下，初级c 关于我们 在大肠癌细胞的培养中，我们发现BM是由癌细胞自身产生的。接下来，我们已经检查了产生BM的能力与其层粘连蛋白受体（VLA-6）之间的相关性。VLA-6在BMPC和非BMPC的癌细胞胞浆中均有表达，提示BMPC产生BM的能力与层粘连蛋白受体无关。肝动脉灌注组和对照组肝转移复发率分别为5.3%和14.2%。在BMPC中，肝动脉灌注组和对照组的肝转移复发率分别为16.7%和66.7%，为进一步阐明结直肠癌肝转移的机制，我们将制作大鼠自然肝转移模型。我们将进行白细胞介素2的免疫化学动脉内治疗以预防肝转移。少

In immunohisochemical study, we have revealed that 35% of colorectal cancer is laminin staining positivity in basement membrane (BM). And we have found that basement membrane producing cancer (BMPC) have been higher frequency of liver metastasis than colorectal cancer without BM (non-BMPC). As for recurrence rate of liver metastasis, the former is 67%, the latter is only 8%. We have examined risk of liver metastasis using BM analysis for laminin, and indicated correlation between BMPC and liver metastasis of colorectal cancer (sensitivity : 75.6%, specificity : 85.7%, accuracy : 83.9%, negative-value : 94.2%) according to that, we could predict risk of liver metastasis.Furthermore, it was seen two types BMPC in immunohistochemical study. One is BM present around each cancer nest (type A), and other was BM around several cancer nests (type B). A significant differences were found between type A and type B in rate of liver metastasis (85.7% and 41.2%, respectively). As compared primary c … More ulture cells of colorectal cancer, we found that the BM was produced by cancer cells themselves. Next, we have examined correlation between ability of producing BM and their laminin receptor (VLA-6). The expression of VLA-6 was seen in cytoplasms of cancer cells both BMPC and non-BMPC.Therefore it might be seen that ability of producing BM was independent of laminin receptor.We performed hepatic arterial infusion therapy using mitomycin-C (MMC) and 5-fluorouracil (5-FU) in postoperative patients to protect liver metastasis. The recurrence rate of liver metastasis in hepatic arterial infusion group and in control group were 5.3% and 14.2%, respectively. In BMPC, recurrence rate of liver metastasis in hepatic arterial infusion group and in control group was 16.7% and 66.7%, respectively.In the future, for elucidated as the machanisms of the liver metastasis of colorectal cancer, we make model rat of natural liver metastasis. And we will perform immunochemical intraarterial therapy with interleukin 2 for prevention of liver metastasis. Less